Managed Access Programs for INC280, Capmatinib

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

NCT04427072 ·Status: TERMINATED ·Phase: PHASE3

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

NCT06161051 ·Status: COMPLETED

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

NCT05642572 ·Status: RECRUITING ·Phase: PHASE2

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

NCT05488314 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations

NCT05796726 ·Status: COMPLETED

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

NCT02414139 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874 ·Status: NO_LONGER_AVAILABLE

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

NCT04816214 ·Status: TERMINATED ·Phase: PHASE3

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

NCT06988475 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer

NCT04599712 ·Status: APPROVED_FOR_MARKETING

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158 ·Status: NO_LONGER_AVAILABLE

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

NCT04077099 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489 ·Status: RECRUITING

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

NCT06762327 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

NCT00005989 ·Status: COMPLETED ·Phase: PHASE2

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

NCT01287754 ·Status: COMPLETED ·Phase: PHASE4

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NCT06054191 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

NCT02876081 ·Status: WITHDRAWN ·Phase: PHASE2

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

NCT00579683 ·Status: COMPLETED

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT03599518 ·Status: TERMINATED ·Phase: PHASE1

An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00949910 ·Status: COMPLETED ·Phase: PHASE4

Study on the Mechanism of Acquired Resistance of Entrectinib

NCT07199959 ·Status: RECRUITING

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 ·Status: RECRUITING ·Phase: PHASE3